Indeed, a comparison of gene expression in psoriasis patients between responders to etanercept, a TNF-α inhibitor, and non-responders revealed that the responsiveness is dependent on inactivation of the Th17 immune response [42]. The gene discussed is TNF; the disease is psoriasis.